- Home
- TOL vs BMRN Comparison
TOL vs BMRN Comparison
Compare TOL & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TOL | BMRN |
|---|---|---|
| Founded | 1967 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.5B | 12.3B |
| IPO Year | 1994 | 1999 |
Fundamental Metrics
Financial Performance| Metric | TOL | BMRN |
|---|---|---|
| Price | $134.45 | $54.85 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 20 | 27 |
| Target Price | ★ $170.88 | $91.62 |
| AVG Volume (30 Days) | 831.1K | ★ 1.9M |
| Earning Date | 08-18-2026 | 10-26-2026 |
| Dividend Yield | ★ 0.77% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 7.87 | 0.77 |
| Revenue | ★ $7,143,258,000.00 | $1,313,646,000.00 |
| Revenue This Year | N/A | $21.29 |
| Revenue Next Year | $1.72 | $14.45 |
| P/E Ratio | ★ $17.13 | $71.44 |
| Revenue Growth | N/A | ★ 17.62 |
| 52 Week Low | $123.15 | $49.26 |
| 52 Week High | $168.36 | $70.98 |
Technical Indicators
Market Signals| Indicator | TOL | BMRN |
|---|---|---|
| Relative Strength Index (RSI) | 42.83 | 21.32 |
| Support Level | $130.85 | $53.53 |
| Resistance Level | $153.78 | $57.95 |
| Average True Range (ATR) | 3.17 | 1.48 |
| MACD | 0.39 | -0.81 |
| Stochastic Oscillator | 36.98 | 6.51 |
Price Performance
Historical ComparisonAbout TOL Toll Brothers Inc.
Toll Brothers is the leading luxury homebuilder in the United States with an average sale price well above that of public competitors. The company operates in over 60 markets across 24 states and caters to move-up, active-adult, and second-homebuyers. Toll Brothers consistently ranks as a top 10 builder in the US based on total home closings. Traditional homebuilding operations represent most of the company's revenue. Toll Brothers also builds luxury for-sale and for-rent properties in urban centers across the US. Its headquarters are in Horsham, Pennsylvania.
About BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.